Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2017-06-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
第五届董事会第十七次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the 17th meeting of the 5th Board of Directors of 嘉事堂药业股份有限公司. It details the approval of proposals related to terminating a share issuance and related asset purchase, and the scheduling of a second extraordinary shareholders' meeting. The document includes voting results and references to compliance with company law and internal rules. There are no financial statements, audit opinions, or detailed financial data presented. The document is a formal announcement of board decisions, which fits the category of Board/Management Information (MANG). The document length is short (1419 characters), and it is not a report or presentation but an official board meeting resolution announcement.
2017-06-29 Chinese
2016年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2016 annual equity distribution (dividend) plan approved at the 2017 shareholders' meeting. It details the dividend amount per share, the record date, the ex-dividend date, the dividend payment method, and the shareholders entitled to the dividend. There are no financial statements or comprehensive financial data presented, only the dividend distribution details. The document is short (2014 characters) and serves as an official announcement of dividend payment details rather than a full report or financial statement. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2017-06-22 Chinese
第五届董事会第十六次会议决议的公告
Board/Management Information Classification · 95% confidence The document is a formal announcement from the board of directors of 嘉事堂药业股份有限公司 regarding the resolutions passed at the fifteenth meeting of the fifth board. It details the termination of a major asset restructuring plan involving issuance of shares to purchase assets and related agreements, including the withdrawal of the application to the China Securities Regulatory Commission. The document includes voting results and mentions compliance with company law and internal rules. It is not a full financial report, audit, or earnings release, nor is it a presentation or proxy solicitation. It is a board meeting resolution announcement related to management decisions and corporate actions. Therefore, it fits best under Board/Management Information (MANG). The document length is 2443 characters, which is typical for such announcements and not a full report. Confidence is high due to clear references to board meeting resolutions and management decisions.
2017-06-19 Chinese
独立董事关于公司终止发行股份购买资产暨关联交易事项并撤回申请文件的事前认可意见
Board/Management Information Classification · 95% confidence The document is an opinion statement from the independent directors of 嘉事堂药业股份有限公司 regarding the termination of a share issuance for asset purchase and related party transaction, and the withdrawal of the application documents. It references regulatory rules related to major asset restructuring and independent director systems. The document is a formal pre-approval opinion rather than a full report or announcement of financial results. It does not contain financial statements or detailed financial data, nor is it a general regulatory announcement or a report publication notice. It is a specific management/board-related opinion on a corporate action, which aligns best with Board/Management Information (MANG) as it concerns board decisions and management opinions on corporate transactions.
2017-06-19 Chinese
终止发行股份购买资产暨关联交易事项并撤回相关申请文件的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from 嘉事堂药业股份有限公司 regarding the termination of a planned issuance of shares to purchase assets and related party transactions, as well as the withdrawal of the related application documents. It details the procedural history, regulatory interactions with the China Securities Regulatory Commission (CSRC), board and supervisory committee approvals, independent director opinions, and financial advisor verification. The document is focused on the cessation of a major asset restructuring transaction and the withdrawal of the application, rather than presenting financial results, audit opinions, or detailed financial statements. It is not a full annual or interim report, nor is it a call transcript or earnings release. The document is a formal announcement about a capital/financing update related to a major asset purchase and share issuance plan that is now terminated. Given the content and context, the most appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters, but it contains substantive information about the termination of a financing transaction, not merely a report publication announcement or a brief notice. Therefore, CAP is the best fit with high confidence.
2017-06-19 Chinese
独立董事关于公司终止发行股份购买资产暨关联交易事项并撤回申请文件的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of 嘉事堂药业股份有限公司 regarding the termination of a share issuance for asset purchase and related party transaction, and the withdrawal of the application documents. It references compliance with laws and regulations related to major asset restructuring and board meeting procedures. The document is a formal opinion letter, not a full report or financial statement. It does not contain financial data or detailed financial analysis, nor is it a regulatory announcement or certification letter. It is a standalone opinion related to a corporate transaction and governance matter, which fits best under the category of Regulatory Filings (RNS) as it does not fit other more specific categories like M&A filings or management reports. The document length is short (894 characters), and it is not an announcement of a report publication but an independent opinion letter.
2017-06-19 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.